Strong Sales Growth in Q1 FY2024 (April to June 2023)

NZX/ASX Announcement

15 August 2023

Strong Sales growth in Q1 FY2024 (April to June 2023)

Highlights

• TruScreen experiences strong sales growth in Q1 FY24
• Product sales up 100% Q1 2024/Q1 2023 and SUS sales up 73% to 56,160 units for the
quarter
• China continues to grow strongly with contributions from new Health Check sector

Truscreen Group Limited (NZX/ASX:TRU) is pleased to report a 100% growth in sales over the
same quarter year on year and a 73% growth in sales of Single Use Sensor (SUS) for the same
period.
China continues to drive the growth, and demand is returning to pre COVID levels. The
commencement of the Health Check project which aims to screen 10,000 women in the next 3 years
also contributed to the sales growth.
The endorsement of TruScreen's AI-enabled technology in the latest edition of CSCCP's China
Cervical Cancer Screening Guideline, published in the July 2023 edition of CSCCP's journal, Chinese
Journal of Clinical Gynaecology and Obstetrics, and the recent endorsement in the prestigious Blue
Book in China, are enabling our distributor Siweixiangtai Tech Co. Ltd (SWXT) to capitalise on the
rapid growth in demand.
The CEO, Dr Beata Edling commented:
“I am delighted to report on our Q1 results. A recent trip to Asia and Eastern Europe has confirmed
that our efforts in co-investing with our committed distributors are paying off and that the distributors
are poised to capture the rapid growth in demand for TruScreen’s technology.
We have invested considerable resources in developing Vietnam, Saudi Arabia and Zimbabwe, and
expect that our distributors will broaden our installed base of TruScreen business in their regions in
the coming years”.

This announcement has been approved by the Board.

Ends

For more information, visit www.truscreen.com or contact:




Dr Beata Edling
Chief Executive Officer
beataedling@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com





About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and
manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via
measurements of the low level of optical and electrical stimuli.
TruScreen’s cervical screening technology enables cervical screening, negating sampling and
processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,
specialised personnel and supporting laboratory infrastructure.
The TruScreen device, TruScreen Ultra
®
, is registered as a primary screening device for cervical
cancer screening.
The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the
TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and
COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the
Philippines, among others and has distributors in 29 countries. In 2021, TruScreen established a
manufacturing facility in China for devices marketed and sold in China.
TruScreen technology has been recognised in CSCCP’s (Chinese Society for Colposcopy and
Cervical Pathology) China Cervical Cancer Screening Management Guideline.
TruScreen has been recognised in a China Blue Paper “Cervical Cancer Three Stage Standardized
Prevent and Treatment” published on 28 April 2023.
In financial year 2023 alone, over 140000* examinations have been performed
with TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam,
Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen’s vision is “A world without the cervical
cancer”
©
.
To learn more, please visit: www.truscreen.com/.
*Based on Single Use Sensor sales.

Glossary:
Pap smear (the Papanicolaou smear) test involves gathering a sample of cells from the cervix, with a special
brush. The sample is placed on a glass slide or in a bottle containing a solution to preserve the cells. Then it is
sent to a laboratory for a pathologist to examine under a microscope. https://www.cancer.net/navigating-
cancer-care/diagnosing-cancer/tests-and-procedures/pap-test
LBC (the liquid-based cytology) test, transfers a thin layer of cells, collected with a brush from the cervix,
onto a slide after removing blood or mucus from the sample. The sample is preserved so other tests can be
done at the same time, such as the human papillomavirus (HPV) test https://www.cancer.net/cancer-
types/cervical-cancer/diagnosis

HPV (human papilloma virus) test is done on a sample of cells removed from the cervix, the same sample
used for the Pap test or LBC. This sample is tested for the strains of HPV most commonly linked to cervical
cancer. HPV testing may be done by itself or combined with a Pap test and/or LBC. This test may also be
done on a sample of cells which a person can collect on their own.
https://www.cancer.net/cancer-
types/cervical-cancer/screening-and-prevention

Sensitivity and specificity mathematically describe the accuracy of a test which reports the presence
or absence of a condition. If individuals who have the condition are considered "positive" and those who
don't are considered "negative", then sensitivity is a measure of how well a test can identify true positives
and specificity is a measure of how well a test can identify true negatives:
• Sensitivity (true positive rate) is the probability of a positive test result, conditioned on the
individual truly being positive.
• Specificity (true negative rate) is the probability of a negative test result, conditioned on the
individual truly being negative (Sensitivity and specificity – Wikipedia).
For more information about the cervical cancer and cervical cancer screening in New Zealand and Australia,
please see useful links:
New Zealand: National Cervical Screening Programme | National Screening Unit (nsu.govt.nz)

Australia: Cervical cancer | Causes, Symptoms & Treatments | Cancer Council